Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Cancer Biother Radiopharm 2009 Jun;24(3):321-5

California Pacific Medical Center, San Francisco, CA 94115, USA.

The anti-CTLA4 antibody, ipilimumab, has shown clinical activity against melanoma. Diarrhea due to immune-related colitis is the most frequent serious toxicity and, if untreated, may lead to intestinal perforation. Diarrhea treatment guidelines were developed based on clinical experience in over 2000 patients treated with ipilimumab, and these safety guidelines recommend systemic steroids as the first choice for the treatment of severe diarrhea. In this article, we present an alternative approach to the control of immune-related colitis by using the antitumor necrosis factor antibody, infliximab. Patients with metastatic melanoma received ipilimumab 10 mg/kg every 3 weeks for 4 doses, then every 3 months. Those who developed grade 2 diarrhea were treated with infliximab 5 mg/kg weeks 0 and 2 with mesalamine and loperamide. Steroids were given only for refractory cases requiring hospitalization. Of the first 3 cases of ipilimumab-induced diarrhea, 2 proved refractory and required hospitalization, but 1 recovered quickly without systemic steroids. We then added hydrocortisone enemas daily to the above regimen, and the next 3 patients recovered from grade 2 ipilimumab-induced colitis without difficulty. Treatment with infliximab, mesalamine, and hydrocortisone enemas may produce a rapid improvement in ipilimumab-induced colitis and avoid the administration of systemic steroids.

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2008.0607DOI Listing
June 2009
45 Reads

Publication Analysis

Top Keywords

immune-related colitis
12
systemic steroids
12
ipilimumab-induced colitis
8
mg/kg weeks
8
antibody ipilimumab
8
hydrocortisone enemas
8
anti-ctla4 antibody
8
colitis
5
diarrhea
5
necrosis factor
4
factor antibody
4
antitumor necrosis
4
infliximab
4
antibody infliximab
4
patients recovered
4
regimen patients
4
treatment infliximab
4
daily regimen
4
metastatic melanoma
4
patients metastatic
4

Altmetric Statistics

Similar Publications